CL2017002826A1 - Cepa bacteriana que reduce la señalización del dolor y altera la motilidad gastrointestinal; composición que la comprende; uso de dicha composición para tratar la constipación o cólicos; uso de dicha composición para tratar o reducir el riesgo de desarrollar síndrome del intestino irritable.(solicitud divisional 490-2015) - Google Patents

Cepa bacteriana que reduce la señalización del dolor y altera la motilidad gastrointestinal; composición que la comprende; uso de dicha composición para tratar la constipación o cólicos; uso de dicha composición para tratar o reducir el riesgo de desarrollar síndrome del intestino irritable.(solicitud divisional 490-2015)

Info

Publication number
CL2017002826A1
CL2017002826A1 CL2017002826A CL2017002826A CL2017002826A1 CL 2017002826 A1 CL2017002826 A1 CL 2017002826A1 CL 2017002826 A CL2017002826 A CL 2017002826A CL 2017002826 A CL2017002826 A CL 2017002826A CL 2017002826 A1 CL2017002826 A1 CL 2017002826A1
Authority
CL
Chile
Prior art keywords
composition
treat
risk
reduce
gastrointestinal motility
Prior art date
Application number
CL2017002826A
Other languages
English (en)
Inventor
Eamonn Connolly
John Bienenstock
Wolfgang Kunze
Original Assignee
Biogaia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49115523&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017002826(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogaia Ab filed Critical Biogaia Ab
Publication of CL2017002826A1 publication Critical patent/CL2017002826A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T7/00—Image analysis
    • G06T7/0002—Inspection of images, e.g. flaw detection
    • G06T7/0012—Biomedical image inspection
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T7/00—Image analysis
    • G06T7/10—Segmentation; Edge detection
    • G06T7/13—Edge detection
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
    • G06T2207/00—Indexing scheme for image analysis or image enhancement
    • G06T2207/30—Subject of image; Context of image processing
    • G06T2207/30004—Biomedical image processing
    • G06T2207/30092—Stomach; Gastric

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Theoretical Computer Science (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Medical Informatics (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Toxicology (AREA)
  • Quality & Reliability (AREA)
  • Radiology & Medical Imaging (AREA)

Abstract

<p>UNA CEPA BACTERIANA QUE REDUCE LA SEÑALIZACIÓN DEL DOLOR MEDIANTE LA REDUCCIÓN DEL DISPARO NERVIOSO AFERENTE MESENTÉRICO Y ALTERE LA MOTILIDAD GASTROINTESTINAL EN UN SUJETO, DONDE DICHA CEPA SE SELECCIONA DE LACTOHACILLUS GASSERI 345A (LG345A) DEPOSITADA EN DSMZ BAJO EL NO. DE ACCESO DSM-27123, LACTOBACILLUS GASSERI 621A (LG621A) DEPOSITADA EN DSMZ BAJO EL NO. DE ACCESO DSM-27126 O LACTOBACILLUS REUTEN DEPOSITADA EN DSMZ BAJO EL NO. DE ACCESO DSM 17938. UNA COMPOSICIÓN QUE COMPRENDE UNA DE DICHAS CEPAS BACTERIANAS. USO DE DICHA COMPOSICIÓN PARA TRATAR LA CONSTIPACIÓN O CÓLICOS O REDUCIR EL RIESGO DE DESARROLLAR CONSTIPACIÓN O CÓLICOS EN UN SUJETO. USO DE DICHA COMPOSICIÓN PARA TRATAR O REDUCIR EL RIESGO DE DESARROLLAR SÍNDROME DEL INTESTINO IRRITABLE EN DICHO SUJETO.</p>
CL2017002826A 2012-09-03 2017-11-08 Cepa bacteriana que reduce la señalización del dolor y altera la motilidad gastrointestinal; composición que la comprende; uso de dicha composición para tratar la constipación o cólicos; uso de dicha composición para tratar o reducir el riesgo de desarrollar síndrome del intestino irritable.(solicitud divisional 490-2015) CL2017002826A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261696277P 2012-09-03 2012-09-03

Publications (1)

Publication Number Publication Date
CL2017002826A1 true CL2017002826A1 (es) 2018-04-06

Family

ID=49115523

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2015000490A CL2015000490A1 (es) 2012-09-03 2015-02-27 Método para la selección de agentes para el tratamiento de un trastorno de la motilidad intestinal; cepa bacteriana seleccionada por el método; y método de tratamiento.
CL2017002826A CL2017002826A1 (es) 2012-09-03 2017-11-08 Cepa bacteriana que reduce la señalización del dolor y altera la motilidad gastrointestinal; composición que la comprende; uso de dicha composición para tratar la constipación o cólicos; uso de dicha composición para tratar o reducir el riesgo de desarrollar síndrome del intestino irritable.(solicitud divisional 490-2015)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2015000490A CL2015000490A1 (es) 2012-09-03 2015-02-27 Método para la selección de agentes para el tratamiento de un trastorno de la motilidad intestinal; cepa bacteriana seleccionada por el método; y método de tratamiento.

Country Status (27)

Country Link
US (5) US9555065B2 (es)
EP (2) EP2893045B1 (es)
JP (3) JP6259458B2 (es)
KR (1) KR102293438B1 (es)
CN (4) CN108904545A (es)
AU (1) AU2013308299B2 (es)
CA (1) CA2883440A1 (es)
CL (2) CL2015000490A1 (es)
CO (1) CO7350654A2 (es)
DK (1) DK2893045T3 (es)
ES (1) ES2681974T3 (es)
GE (1) GEP201706775B (es)
HK (3) HK1211848A1 (es)
HR (1) HRP20181033T1 (es)
IL (2) IL237397B (es)
IN (1) IN2015DN01572A (es)
LT (1) LT2893045T (es)
MX (2) MX362495B (es)
MY (2) MY182358A (es)
NZ (1) NZ705358A (es)
PH (1) PH12015500452A1 (es)
RU (1) RU2701348C2 (es)
SG (3) SG10202101556WA (es)
SI (1) SI2893045T1 (es)
UA (2) UA118339C2 (es)
WO (1) WO2014033330A1 (es)
ZA (1) ZA201501472B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2013109251A (ru) 2010-08-04 2014-09-10 Томас Джулиус БОРОДИ Композиции для трансплантации фекальной флоры и способы их получения и применения и устройства для их доставки
CN108094541A (zh) * 2018-01-11 2018-06-01 黑龙江完达山林海液奶有限公司 一种具有保健益生功能的风味发酵乳及其制备方法
HUE059963T2 (hu) 2018-07-24 2023-01-28 Biogaia Ab Melatonintámogató baktériumok szelektálása és felhasználása az infantilis kólika csökkentésére
CN113966284A (zh) * 2019-06-05 2022-01-21 Avl动力工程公司 车辆轴组件
CN110186922B (zh) * 2019-06-25 2021-07-23 西安交通大学医学院第一附属医院 一种监测结肠移行性复合运动的实验装置及方法
US11843097B2 (en) 2019-09-10 2023-12-12 Avl Powertrain Engineering, Inc. Power supply control systems and methods
CN112710823B (zh) * 2020-12-17 2024-03-29 中国科学院深圳先进技术研究院 一种肠移行性复合运动的离体检测***及其应用
CN114342878B (zh) * 2022-01-10 2022-09-30 南京鼓楼医院 一种慢传输型便秘动物模型的建立方法
CN117384804A (zh) * 2023-12-12 2024-01-12 北京三元食品股份有限公司 格氏乳杆菌b1-26及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5438989A (en) * 1990-08-10 1995-08-08 Hochman; Darryl Solid tumor, cortical function, and nerve tissue imaging methods and device
PL200132B1 (pl) * 1998-08-21 2008-12-31 Novartis Ag Zastosowanie 3-(5-metoksy-1H-indol-3-ilometyleno)-N-pentylokarbazyimidoamidu
EP1196164A2 (en) * 1999-07-06 2002-04-17 Enpharma L.P. Methods and compositions for regulating gut motility and food intake
EP1384483A1 (en) * 2002-07-23 2004-01-28 Nestec S.A. Probiotics for treatment of irritable bowel disease (IBS) through improvement of gut neuromuscular function
TWI241912B (en) * 2002-10-30 2005-10-21 Food Industry Res & Dev Inst Novel Acid-and bile salt-resistant Lactobacillus isolates having the ability to lower and assimilate cholesterol
CN1663573B (zh) * 2004-03-04 2010-04-28 青岛东海药业有限公司 一种稳定安全的微生态制剂及其制备方法和用途
US20090233888A1 (en) * 2005-03-23 2009-09-17 Usc Stevens, University Of Southern California Treatment of disease conditions through modulation of hydrogen sulfide produced by small intestinal bacterial overgrowth
JP5036020B2 (ja) * 2005-11-30 2012-09-26 雪印メグミルク株式会社 腎周囲脂肪蓄積抑制剤
US7374924B2 (en) * 2006-06-05 2008-05-20 Biogaia Ab Use of selected lactic acid bacteria for reducing infantile colic
JP5019563B2 (ja) * 2006-06-16 2012-09-05 旭化成ケミカルズ株式会社 腸内細菌賦活剤
EP2200443B2 (en) * 2007-09-17 2021-06-30 Cornell University Branched chain fatty acids for prevention or treatment of gastrointestinal disorders
MX2012001362A (es) * 2009-07-31 2012-02-22 Nestec Sa Composicion nutricional para lactantes o mascotas alimentados con leche maternal con probioticos y nutrientes seleccionados.
US20110110905A1 (en) * 2009-11-06 2011-05-12 Ritchie Jennifer A Infant Colic Supplement
WO2011148219A1 (en) * 2010-05-28 2011-12-01 Compagnie Gervais Danone Probiotic strains for use in improving the enteric nervous system
US20120034198A1 (en) * 2010-08-04 2012-02-09 Microbios, Inc. Carriers for storage and delivery of biologics
CN102304489B (zh) * 2011-09-23 2013-06-12 北京龙科方舟生物工程技术有限公司 一株罗伊氏乳杆菌及其应用

Also Published As

Publication number Publication date
US10174388B2 (en) 2019-01-08
MX362495B (es) 2019-01-21
HK1258774A1 (zh) 2019-11-22
LT2893045T (lt) 2018-07-25
GEP201706775B (en) 2017-11-27
UA126374C2 (uk) 2022-09-28
AU2013308299A1 (en) 2015-03-26
CN108904545A (zh) 2018-11-30
HRP20181033T1 (hr) 2018-08-24
SG10201608055XA (en) 2016-11-29
EP2893045B1 (en) 2018-05-16
SG10202101556WA (en) 2021-03-30
JP2018090616A (ja) 2018-06-14
US20180023150A1 (en) 2018-01-25
US9816150B2 (en) 2017-11-14
KR20150048201A (ko) 2015-05-06
CA2883440A1 (en) 2014-03-06
DK2893045T3 (en) 2018-07-30
AU2013308299B2 (en) 2019-04-18
EP2893045A1 (en) 2015-07-15
US20170114422A1 (en) 2017-04-27
US9555065B2 (en) 2017-01-31
JP2015529329A (ja) 2015-10-05
IN2015DN01572A (es) 2015-07-03
MY195532A (en) 2023-01-31
CO7350654A2 (es) 2015-08-10
IL259652A (en) 2018-07-31
JP6476328B2 (ja) 2019-02-27
HK1258778A1 (zh) 2019-11-22
US20150231186A1 (en) 2015-08-20
CN108753645A (zh) 2018-11-06
UA118339C2 (uk) 2019-01-10
WO2014033330A1 (en) 2014-03-06
CN104918640A (zh) 2015-09-16
US20190112676A1 (en) 2019-04-18
IL237397B (en) 2018-10-31
EP3369808A1 (en) 2018-09-05
RU2701348C2 (ru) 2019-09-26
SG11201501297TA (en) 2015-03-30
CL2015000490A1 (es) 2015-05-29
SI2893045T1 (en) 2018-08-31
CN104918640B (zh) 2019-03-19
MY182358A (en) 2021-01-20
KR102293438B1 (ko) 2021-08-25
JP6259458B2 (ja) 2018-01-10
PH12015500452A1 (en) 2015-04-20
MX2018013097A (es) 2020-09-02
CN108753645B (zh) 2019-10-22
ES2681974T3 (es) 2018-09-17
JP2018029588A (ja) 2018-03-01
MX2015002792A (es) 2015-05-07
RU2015112102A (ru) 2016-10-20
JP6322326B2 (ja) 2018-05-09
HK1211848A1 (en) 2016-06-03
NZ705358A (en) 2018-09-28
IL259652B (en) 2020-03-31
US20220306984A1 (en) 2022-09-29
ZA201501472B (en) 2016-06-29
IL237397A0 (en) 2015-04-30
CN109966511A (zh) 2019-07-05

Similar Documents

Publication Publication Date Title
CL2017002826A1 (es) Cepa bacteriana que reduce la señalización del dolor y altera la motilidad gastrointestinal; composición que la comprende; uso de dicha composición para tratar la constipación o cólicos; uso de dicha composición para tratar o reducir el riesgo de desarrollar síndrome del intestino irritable.(solicitud divisional 490-2015)
MX2022005323A (es) Novedosos lactobacillus que tienen diversas funciones, y uso de los mismos.
ES2550059T3 (es) Método para usar una cepa de Bacillus subtilis para la profilaxis y el tratamiento de afecciones gastrointestinales
AU2017279037A1 (en) New medical use of probiotics
MX2020012602A (es) Composiciones bacterianas dise?adas y usos de las mismas.
MY160412A (en) Oral compositions containing extracts of zingiber officinale and related methods
MX2015011700A (es) Uso de la bacteria faecalibacterium prausnitzii htf-f (dsm 26943) para suprimir la inflamacion.
MX2015015341A (es) Cepas de salmonella para uso en el tratamiento y/o prevencion de cancer.
WO2015047941A3 (en) Compositions and methods for treatment and prophylaxis of gastrointestinal diseases
MX2021009001A (es) Composiciones microbianas para alimentacion directa y sus metodos de uso.
MX2021009398A (es) Composiciones probioticas que comprenden cepas de lactobacillus reuteri y metodos de uso.
CL2009000905A1 (es) Composicion comestible que comprende bifidobacterium longum atcc baa-999; y su uso para tratar o prevenir la ansiedad y/o desordenes relacionados con ansiedad.
MY155299A (en) Oral dosage composition
MY152710A (en) Oral compositions containing extracts of garcinia mangostana l. and related methods
MX2015014181A (es) 2-acetilnafto [2,3-b]furano -4,9-diona para uso en el tratamiento del cáncer.
CL2011002597A1 (es) Compuestos derivados de rifamicina; procedimiento de preparacion; composicion farmaceutica; su uso para tratar, prevenir o aliviar sobrecrecimiento bacteriano en trastornos intestinales tales como sindrome de colon irritable, diarrea del viajante, enfermedad de crohn, encefalopatia hepatica y enteritis.
CL2011001939A1 (es) Uso de lactobacillus helveticus cncm i-4095 para apoyar la perdida de peso y/o mantenimiento del peso en humanos y/o animales, particularmente para tratar la obesidad y trastornos metabólicos; y microorganismo de la cepa de lactobacillus helveticus cncm i-4095.
CL2011001937A1 (es) Uso de la cepa de lactobacillus rhamnosus cncm i-4096 para apoyar la pérdida de peso y/o mantenimiento del peso en humanos y/o animales, específicamente para el tratamiento de la obesidad.
CL2018001936A1 (es) Nueva cepa bacteriana probiótica de lactobacillus plantarum y composiciones y usos de la misma en el tratamiento de la inflamación.
MX2021003224A (es) Combinacion de probioticos para el tratamiento de trastornos gastrointestinales relacionados con la inflamacion.
BR112017023636A2 (pt) suplemento dietético
MX2017005812A (es) Composiciones de limpieza.
CL2017001818A1 (es) Bacteria de ácido láctico y su uso para el tratamiento de mastitis
UA113399C2 (xx) Штам непатогенної грамнегативної бактерії та його застосування в дерматології
EA201690768A1 (ru) Состав, предотвращающий некротический энтерит у домашних птиц